Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Vifor Pharma AG
  6. News
  7. Summary
    VIFN   CH0364749348

VIFOR PHARMA AG

(VIFN)
  Report
Delayed Swiss Exchange  -  11:31 2022-08-12 am EDT
168.95 CHF   +0.24%
08/11GLOBAL MARKETS LIVE : Walt Disney, Bank of America, Sonos, ABB, Roche...
MS
08/10Australia's CSL Closes Vifor Pharma Purchase
MT
08/10CSL Completes Vifor Pharma Acquisition
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

VAT To Replace Vifor Pharma On Swiss Leader Index

03/24/2022 | 03:43am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BACHEM HOLDING AG 2.75% 69.15 Delayed Quote.-53.00%
MEYER BURGER TECHNOLOGY AG -1.80% 0.572 Delayed Quote.43.12%
SENSIRION HOLDING AG 1.91% 117.4 Delayed Quote.-13.64%
VAT GROUP AG -2.64% 265.8 Delayed Quote.-39.92%
VIFOR PHARMA AG 0.24% 168.95 Delayed Quote.3.88%
All news about VIFOR PHARMA AG
08/11GLOBAL MARKETS LIVE : Walt Disney, Bank of America, Sonos, ABB, Roche...
MS
08/10Australia's CSL Closes Vifor Pharma Purchase
MT
08/10CSL Completes Vifor Pharma Acquisition
MT
08/08VIFOR PHARMA AG(SWX : VIFN) dropped from S&P Global BMI Index
CI
08/08VIFOR PHARMA AG(SWX : VIFN) dropped from S&P EUROPE 350 - Pharmaceuticals, Biotechnology &..
CI
08/08VIFOR PHARMA AG(SWX : VIFN) dropped from S&P EUROPE 350 - Health Care
CI
08/08VIFOR PHARMA AG(SWX : VIFN) dropped from S&P EUROPE 350
CI
08/08VIFOR PHARMA AG(SWX : VIFN) dropped from S&P Global 1200
CI
08/08VIFOR PHARMA AG(SWX : VIFN) dropped from S&P International 700
CI
08/05VIFOR PHARMA AG(SWX : VIFNE) dropped from FTSE All-World Index
CI
More news
Analyst Recommendations on VIFOR PHARMA AG
More recommendations
Financials
Sales 2022 2 005 M 2 125 M 2 125 M
Net income 2022 346 M 366 M 366 M
Net cash 2022 645 M 683 M 683 M
P/E ratio 2022 40,4x
Yield 2022 1,28%
Capitalization 10 963 M 11 624 M 11 624 M
EV / Sales 2022 5,15x
EV / Sales 2023 4,51x
Nbr of Employees 2 200
Free-Float 99,8%
Chart VIFOR PHARMA AG
Duration : Period :
Vifor Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIFOR PHARMA AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Last Close Price 168,95 CHF
Average target price 163,25 CHF
Spread / Average Target -3,37%
EPS Revisions
Managers and Directors
Shah Abbas Hussain Chief Executive Officer
Alexandros Sigalas Chief Financial Officer
Jacques Theurillat Chairman
Klaus Henning Jensen Chief Medical Officer
Frédéric Zwahlen Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
VIFOR PHARMA AG3.88%11 631
JOHNSON & JOHNSON-2.30%439 441
ELI LILLY AND COMPANY9.03%286 164
ROCHE HOLDING AG-18.19%272 759
PFIZER, INC.-18.22%271 020
ABBVIE INC.4.93%251 211